Literature DB >> 2568261

Effect of bisoprolol on cardiac performance in coronary heart disease.

B Maisch1, U Borst, W Gerhards, G Wagner.   

Abstract

The effects of 5 and 10 mg bisoprolol once daily for 7 days on exercise ECG, myocardial perfusion and left ventricular function in 25 patients with stable coronary heart disease have been assessed in a double-blind, randomized, parallel group trial design. ST-segment depression during exercise was reduced by 56% by 5 mg bisoprolol and by 64% after 10 mg; the difference between the dose levels was significant. Heart rate, systolic and diastolic blood pressure and the rate-pressure product were reduced to similar extent both at rest and during exercise by both doses. Left ventricular thallium-201 scintigrams indicated a significant reduction in myocardial perfusion defects after 10 mg bisoprolol compared to baseline; however, the difference between the two active treatments was not significant. Left atrial and left ventricular diameters obtained by one-dimensional echocardiography, and the calculated shortening fraction, remained unchanged after bisoprolol, and so gave no evidence of a negative inotropic action. It is concluded that 5 mg bisoprolol was effective in once-a-day treatment of angina pectoris due to coronary heart disease, and a further improvement can be expected on increasing the dose to 10 mg.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2568261     DOI: 10.1007/BF00558150

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Summary of short- and long-term studies with bisoprolol in coronary heart disease (CHD).

Authors:  G Wagner
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

2.  Acute hemodynamic effects of bisoprolol, a new beta 1 selective adrenoreceptor blocking agent, in patients with coronary artery disease.

Authors:  E Steinmann; M Pfisterer; F Burkart
Journal:  J Cardiovasc Pharmacol       Date:  1986 Sep-Oct       Impact factor: 3.105

3.  A comparison of once daily bisoprolol, 5 and 10 mg, and atenolol 100 mg in the treatment of angina pectoris.

Authors:  M B Maltz; D S Dymond; A W Nathan; A J Camm
Journal:  Eur Heart J       Date:  1987-12       Impact factor: 29.983

4.  Dose-response relationship of the beta-adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis.

Authors:  P Dorow; U Tönnesmann
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Drugs and the heart. VII. Which drug for which disease?

Authors:  L H Opie
Journal:  Lancet       Date:  1980-05-10       Impact factor: 79.321

6.  [201-thallium stress scintigram in patients with coronary artery disease after administration of the cardioselective betablocker atenolol (author's transl)].

Authors:  J Chlup; H J Engel; P Pretschner; P R Lichtlen
Journal:  Z Kardiol       Date:  1981-06

7.  Once daily atenolol (Tenormine) in the treatment of angina pectoris. Observations on clinical efficacy, pharmacokinetics and pharmacodynamics.

Authors:  P A Majid; W J van der Vijgh; P J de Feijter; R Wardeh; E E van der Wall; J P Roos
Journal:  Eur J Cardiol       Date:  1979-06

8.  Comparative effects of nitroglycerin, nifedipine and metoprolol on regional left ventricular function in patients with one-vessel coronary disease.

Authors:  M Pfisterer; L Glaus; F Burkart
Journal:  Circulation       Date:  1983-02       Impact factor: 29.690

9.  Affinity and selectivity of beta-adrenoceptor antagonists in vitro.

Authors:  A Wellstein; D Palm; G G Belz
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

10.  Noninvasive assessment of left ventricular performance after administration of bisoprolol.

Authors:  R J Esper; R C Esper; O H Burrieza; J Menna
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

View more
  1 in total

1.  Comparison of casual, ambulatory and self-measured blood pressure in a study of nitrendipine vs bisoprolol.

Authors:  T Mengden; B Bättig; M Schubert; T Jeck; B Weisser; C Buddeberg; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.